VALNEVA Announces the First Ever Marketing Approval in Europe for a Vaccine Produced in the EB66(R) Cell Line

valneva logo

May 19, 2014

European biotechnology company Valneva SE (Valneva) announced today the first ever marketing approval in Europe for a vaccine produced in the EB66® cell line. The marketing authorization was granted by the European Medicines Agency (EMA) for the prevention of Muscovy Duck Parvovirus (MDPV).

Leave a Reply

Your email address will not be published. Required fields are marked *